Abstract
environment. These calculation results can be used to plan future biophysical 23 experiments and may suggest interesting drug design possibilities to address drug 24 resistance due to AcrB function.
25

Importance
26
Addressing the issue of antimicrobial resistance mediated by efflux, this study 27 presents possible binding sites and structures in the AcrB MDR pump that could be 28 molecular targets for drugs. Targeted molecular dynamics simulations suggested that 29 these sites and structures seem vital for a successful efflux. The AcrB is proposed to be 30 divided into three distinct zones, with loops, sheets and helices mediating the passage of 31 molecules from one zone to another. We also described possible capture sites on the 32 outer part of the protein and access ways to its interior. Finally, we proposed that ligand
Introduction 39 40
The multidrug efflux pump AcrB from Escherichia coli, a member of the 41 resistance-nodulation division (RND) family transporters, has been studied extensively 42 as a model for RND efflux pumps that occur in gram-negative bacteria. It is responsible 43 for the capture and extrusion of a wide variety of substrates, like dyes, heavy metals and
44
antibiotics from the cell (1). These efflux pumps contribute to bacterial resistance for 45 many antimicrobial agents and biocides (2), and thus constitute a major public health 46 concern (3). Therefore, it is important to obtain a more detailed understanding of the work, plausible I and F states can be generated using molecular docking calculations.
60
TMD calculations were performed for both ethidium bromide (EtBr) and a 61 tetrahydropyridine derivative NUNL02 (7)(8) ( 
64
The TMD simulations revealed interesting conformational changes in the protein 65 backbone as the ligands progressed through AcrB from the cytosolic interface to the 66 periplasmic surface. These results reinforce the idea of competition as a mechanism of 67 efflux inhibition discussed in (9), in the present work, however, different ligands seem 68 to interfere with transport of each other by utilizing the same transit "pathways" through 69 the protein structure. 
Material and Methods
72
Docking
73
The AcrB structure without bound ligands (PDB ID: 1IWG) (10) is considered 74 to be in the resting state for the transporter and was chosen for the TMD studies. This 75 ligand-free, symmetric homotrimer structure has a resolution of 3.5 Å, and 1053 76 residues in each subunit. The structure is divided into three domains: a transmembrane 77 domain, a pore domain and the TolC interaction domain that together constitute the 78 periplasmic headpiece (10) (11) (Fig. 1) . Some short loop segments, between residues 79 496 and 513, 708 and 716 and 858 and 871, were not resolved in the x-ray structure,
80
and we used Modeller 9.14 (12) (13), with default parameters, to construct them.
81
Experimental results suggest that both EtBr and NUNL02 are substrates for the 82 multidrug efflux pump AcrB (9) (11) (14) . Following the docking methodology 83 described in (9), we used Autodock Tools (15) and AutoDock Vina (16) to locate high-84 affinity binding sites for the substrates EtBr and NUNL02 in chain A of the full AcrB and position E in the TolC domain ( Fig. 1) Fig. 1 and 2 ). We did not attempt to model detailed 
133
All simulations were performed using the AMBER 12 package (21). Atomic 134 charges and any additional missing parameters for EtBr and NUNL02 were generated 
148
For each solvated complex, the protein and ligand atom positions were 149 constrained while water molecules and counterions were relaxed with 500 steps of 150 steepest decent minimization followed by 500 steps of conjugate gradient minimization 151 using an 8 Å nonbonded cutoff. Next, the full protein-ligand complex along with 152 solvent and counterions was relaxed with 1000 steps of steepest descent and 1500 steps 153 of conjugate gradient minimization using a 10 Å nonbonded cutoff and particle-mesh pathway 1 into three distinct zones made it easier to identify residues and structural 187 elements that appear to play an important role in the substrate efflux mechanism (Fig.   188 3).
189
Zone 1 (Fig. 4) is localized to the transmembrane domain. This region has a total prior to ligand entry.
228
As the ligand approaches the boundary of the pore and TolC interaction domains 229 (Fig. 7) , loop 3 undergoes a significant conformational change and loop 4, immediately 230 below loop 3, displays a modest conformational change (Fig. 9, panel a and b) . These (Fig. 9, Table 4 ).
243
There is evidence to suggest that the TolC protein forms a complex with AcrB does not require extensive interaction, e.g., "communication", between the three 275 monomers during the efflux process. This mechanism also implies greater efflux 276 efficiency if all three monomers could function independently. However, our current 277 calculations do not suggest in any way that the trimer cycling mechanism is not also 278 plausible, and the actual efflux mechanism might involve components of both models.
279
In this work, our division of the AcrB protein into three distinct zones is based 280 primarily on our molecular docking studies, which identified stable, intermediate biding 
289
This direct capture mechanism is simple and does not depend upon ancillary proteins, 290 e.g., EmrR or MdfA, to transport ligands to the periplasmic space prior to AcrB capture 291 (27).
292
The transmembrane domain is an -helical bundle that forms a tunnel-like (Table 1) . Access to position C (Fig. 10b) is controlled by conformational changes in 304 loops 1 and 2 (Fig. 8) for efflux pathway 1, and conformational changes in loops 1, 2 305 and 6 (Fig. 11) for efflux pathway 2. Position C appears to correspond closely to a deep 306 binding pocket described previously by Eicher et al. (17) , and loops 1, 2 and/or 6 would 307 correspond to the "switch-loops" they described that control access to the ligand 308 binding pocket.
309
There is also a pair of flexible loops 3 and 4 (Fig. 12 ) that control the exit of 310 ligand from Zone 2, the pore domain, to Zone 3, the TolC domain. Thus, there appears 311 to be a clear "gating" mechanism for ligand entrance and exit in the pore domain. As 
328
The TMD results suggest that, for both pathways, the substrates EtBr and Table 2 641 Zone 1 helix residues displayed in Fig. 4 . 
